Jeffrey J. Bednarski, M.D., Ph.D.

Profile picture
Assistant Professor of Pediatrics, Hematology and Oncology
Researcher, Developmental Biology
Hematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Bednarski's clinical practice focuses on bone marrow transplantation for the treatment of malignant and immunological disorders in children and young adults. Dr. Bednarski is a member of the Primary Immune Deficiency Treatment Consortium and currently has an open clinical trial using a new regimen for bone marrow transplant in patients with immune deficiency. In collaboration with adult oncologists, Dr. Bednarski is also opening a trial using immune cells to treat leukemia.

Dr. Bednarski's research centers on the development of the immune system. During lymphocyte differentiation, the rearrangement of the antigen receptor genes is essential to ensure a diverse and function immune response. This process requires the intentional generation of breaks in DNA at specific locations in the genes. These breaks are subsequently repaired with removal of some DNA and joining of the remaining segments. The DNA breaks pose an extreme risk to the developing cells. Mis-repair can lead to cell death or to translocations that can result in leukemias and lymphomas. Therefore, it is critical that the breaks be carefully managed by cellular processes that ensure proper repair and maintenance of genomic integrity. Dr. Bednarski's research focuses on how the signals from this DNA damage cooperate with other developmental processes to direct lymphocyte differentiation and survival. His overall goals are to understand the signals important for lymphocyte development and how these signals may be corrupted and thus contribute to the generation of leukemia and lymphoma.


  • BS, Summa Cum Laude, Duke University1995
  • PhD, University of Michigan2003
  • MD, Graduation with Distinction in Research, University of Michigan2003


  • Postdoctoral Fellow in Pediatric Hematology-Oncology, Boston Children's Hospital2003 - 2003
  • Resident in Pediatrics, St. Louis Children's Hospital2003 - 2006
  • Clinical Fellow in Pediatric Hematology-Oncology, Washington University School of Medicine2006 - 2009
  • Postdoctoral Fellow in Immunology, Washington University School of Medicine2007 - 2013

Licensure and Board Certification

  • 2006 - PresAmerican Board of Pediatrics, Board Certified
  • 2009 - PresMO, Medical License
  • 2011 - PresPediatric Hematology-Oncology, Board Certified

Honors and Awards

  • Phi Eta Sigma, National Freshman Honor Society1992
  • Golden Key National Honor Society1993
  • National Institute of General Medicine Summer Scholar1993
  • Phi Beta Kappa1994
  • Phi Lambda Upsilon, National Honorary Chemical Society1994
  • Summa cum laude graduate, Duke University1995
  • Regent's Fellowship, University of Michigan Rackham Graduate School1997 - 2001
  • Graduation with Distinction in Research, University of Michigan Medical School2003
  • James P. Keating Ouststanding Resident Award, St. Louis Children's Hospital2005
  • David Gilstrap Memorial Award, St. Louis Children's Hospital2008
  • Hyundai Hope on Wheels Scholar2012 - 2013
  • American Society of Hematology Junior Faculty Scholar Award2018 - Pres
  • Distinguished Service Teaching Award, Washington University School of Medicine2019
  • Department of Pediatrics Faculty Teaching Award2020
  • Department of Pediatrics Faculty Unsung Hero Award2020

Recent Publications view all (33)

Publication Co-Authors

  1. Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. J Clin Immunol. 2020;40(6):901-916. doi:10.1007/s10875-020-00814-6  PMID:32638196 
  2. Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection. Pediatr Blood Cancer. 2020;Jul 24:e28436. doi:10.1002/pbc.28436  PMID:32706439 
  3. DNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent manner. Nat Commun. 2020;11(1):3158. doi:10.1038/s41467-020-16926-x  PMCID:PMC7308414  PMID:32572033 
  4. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol. 2020;11:239. doi:10.3389/fimmu.2020.00239  PMCID:PMC7046837  PMID:32153572 
  5. The Tetraspanin CD53 Regulates Early B Cell Development by Promoting IL-7R Signaling. J Immunol. 2020;204(1):58-67. PMCID:PMC6926393  PMID:31748347 
  6. RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex. Cell Rep. 2019;29(4):829-843.e5. PMID:31644907 
  7. A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease. Pediatr Blood Cancer. 2019;e28030. PMID:31599480 
  8. Safety of Probiotics Among High-Risk Pediatric Hematopoietic Stem Cell Transplant Recipients. Infect Dis Ther. 2019;8(2):301-306. PMCID:PMC6522555  PMID:30989592 
  9. At the intersection of DNA damage and immune responses. Nat Rev Immunol. 2019;19(4):231-242. PMCID:PMC6438741  PMID:30778174 
  10. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2019;25(3):556-561. PMID:30321596 
  11. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018;132(17):1737-1749. PMCID:PMC6202916  PMID:30154114 
  12. Erratum for Franco et al., "A Novel Secreted Protein, MYR1, Is Central to Toxoplasma's Manipulation of Host Cells". MBio. 2018;9(5). PMCID:PMC6168865  PMID:30279290 
  13. Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development. J Exp Med. 2018;215(10):2586-2599. PMCID:PMC6170173  PMID:30158115 
  14. Omenn Syndrome Presenting with Striking Erythroderma and Extreme Lymphocytosis in a Newborn. Pediatr Dermatol. 2017;34(1):e37-e39. PMID:27862277 
  15. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals. J Exp Med. 2016;213(2):209-23. PMCID:PMC4749927  PMID:26834154 
  16. A Novel Secreted Protein, MYR1, Is Central to Toxoplasma's Manipulation of Host Cells. MBio. 2016;7(1):e02231-15. PMCID:PMC4742717  PMID:26838724 
  17. Maternal T-Cell Engraftment Interferes With Human Leukocyte Antigen Typing in Severe Combined Immunodeficiency. Am J Clin Pathol. 2016;145(2):251-7. PMCID:PMC4901308  PMID:26834123 
  18. DNA damage signals inhibit neutrophil function. Blood. 2015;126(26):2773-4. PMCID:PMC4692138  PMID:26705340 
  19. Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma. Immunity. 2015;42(1):186-98. doi:10.1016/j.immuni.2014.12.021  PMCID:PMC4302272  PMID:25607463 
  20. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014;133(2):335-47. doi:10.1016/j.jaci.2013.07.052  PMCID:PMC3960312  PMID:24139498 
  21. The ataxia telangiectasia mutated kinase controls Igκ allelic exclusion by inhibiting secondary Vκ-to-Jκ rearrangements. J Exp Med. 2013;210(2):233-9. doi:10.1084/jem.20121605  PMCID:PMC3570110  PMID:23382544 
  22. Integrated signaling in developing lymphocytes: the role of DNA damage responses. Cell Cycle. 2012;11(22):4129-34. doi:10.4161/cc.22021  PMCID:PMC3524208  PMID:23032308 
  23. RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation. J Exp Med. 2012;209(1):11-7. doi:10.1084/jem.20112078  PMCID:PMC3260864  PMID:22201128 
  24. Lymphocyte development: integration of DNA damage response signaling. Adv Immunol. 2012;116:175-204. doi:10.1016/B978-0-12-394300-2.00006-5  PMID:23063077 
  25. Ataxia telangiectasia mutated (Atm) and DNA-PKcs kinases have overlapping activities during chromosomal signal joint formation. Proc Natl Acad Sci U S A. 2011;108(5):2022-7. doi:10.1073/pnas.1013295108  PMCID:PMC3033293  PMID:21245316 
  26. H2AX prevents CtIP-mediated DNA end resection and aberrant repair in G1-phase lymphocytes. Nature. 2011;469(7329):245-9. doi:10.1038/nature09585  PMCID:PMC3150591  PMID:21160476 
  27. MRN complex function in the repair of chromosomal Rag-mediated DNA double-strand breaks. J Exp Med. 2009;206(3):669-79. doi:10.1084/jem.20081326  PMCID:PMC2699138  PMID:19221393 
  28. A novel benzodiazepine increases the sensitivity of B cells to receptor stimulation with synergistic effects on calcium signaling and apoptosis. J Biol Chem. 2004;279(28):29615-21. doi:10.1074/jbc.M403507200  PMID:15123639 
  29. Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Arthritis Rheum. 2003;48(3):757-66. doi:10.1002/art.10968  PMID:12632430 
  30. Male infertility and thiamine-dependent erythroid hypoplasia in mice lacking thiamine transporter Slc19a2. Mol Genet Metab. 2003;80(1-2):234-41. PMID:14567973 
  31. Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. J Clin Invest. 2002;110(8):1123-32. doi:10.1172/JCI16029  PMCID:PMC150800  PMID:12393848 
  32. The C2 domains of Rabphilin3A specifically bind phosphatidylinositol 4,5-bisphosphate containing vesicles in a Ca2+-dependent manner. In vitro characteristics and possible significance. J Biol Chem. 1998;273(17):10240-8. PMID:9553075 
  33. Function of the htrB high temperature requirement gene of Escherichia coli in the acylation of lipid A: HtrB catalyzed incorporation of laurate. J Biol Chem. 1996;271(20):12095-102. PMID:8662613 
Last updated: 09/18/2020
© 2021 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130